Joomla gallery extension by joomlashine.com
Main Promo Images
Latest news on Friedreich's Ataxia research
Updated results from clinical trials and research initiatives
Friedreich's Ataxia fundraising activities and staying in touch
Participate and stay informed about our fundraising events. Take part in our Facebook community with FA patients, relatives, researchers and friends from all around the world!
Artificial Molecule Helps Stem Cell To Become Nerve Cells
19 Jun 2008 09:56 am
Researchers at the UT Southwestern Medical Center have discovered a molecule that stimulates nerve stem cells to begin maturing into nerve cells in culture. The invention can enable a person's own nerve stem cells to be grown outside the body, stimulated into maturity, and then re-implanted as working nerve cells to treat various diseases.
In the study, rodent nerve stem cells from an area of the brain were cultured with Isx-9. The area of the brain is called hippocampus. The cells are clustered together and developed spiky appendages called neurites, which typically happens when nerve cells are grown in culture. Isx-9 also prevented the stem cells from developing into non-nerve cells and was more potent than other neurogenic substances in stimulating nerve-cell development. The hippocampus, is involved with learning and memory. The stem cells are matured into full-blown nerve cells at a rate of thousands a day. By culturing the stem cells with the compound, the scientists identified a possible biochemical pathway by which stem cells begin to become nerve cells.
Dr. Hsieh of the researchers group, however said that the challenge before them is to find out the ways to control these stem cell.
The research was supported by the Haberecht Wild-Hare Idea Program, the Donald W. Reynolds Foundation, the National Institute of Neurological Disorders and Stroke, the Ellison Medical Foundation, the Welch Foundation and the UT Southwestern President's Research Council.
Source: Science Daily
If you feel like reading an unputdownable novel while collaborating with a just and solidary cause, "The Legacy of Marie Schlau" is your book! 100% of all funds raised will be dedicated to medical research to find a cure for Friedreich's Ataxia, a neurodegenerative disease that affects mostly young people, shortening their life expectancy and confining them to a wheelchair.
The life of Marie Schlau, a German Jewish girl born in 1833 hides great unsolved mysteries: accidents, disappearances, enigmas, unknown diagnoses, disturbing murders, love, tenderness, greed, lies, death ... alternatively a different story unfolds every time and takes us closer to the present. Thus, there are two parallel stories unravelling, each in a different age and place, which surprisingly converge in a revelatory chapter.
Paperback and Kindle versions for "The legacy of Marie Schlau" available for sale at Amazon now!
Currently, BabelFAmily is financing two promising research projects aimed at finding a cure for Friedreich's Ataxia. Whenever you make a donation to us or purchase a copy of "The legacy of Marie Schlau", this is where all funds raised will be devoted to:
1) Gene Therapy for Friedreich's Ataxia research project:
The project is the result of an initiative of Spanish people affected by this rare disease who are grouped in GENEFA in collaboration with the Spanish Federation of Ataxias and the BabelFAmily. The Friedreich’s Ataxia Research Alliance (FARA), one of the main patients’ associations in the United States now joins the endeavour.
2) Frataxin delivery research project:
The associations of patients and families Babel Family and the Asociación Granadina de la Ataxia de Friedreich (ASOGAF) channel 80,000 euros of their donations (50% from each organisation) into a new 18-month project at the Institute for Research in Biomedicine (IRB Barcelona). The project specifically aims to complete a step necessary in order to move towards a future frataxin replacement therapy for the brain, where the reduction of this protein causes the most damage in patients with Friedreich’s Ataxia.
The study is headed by Ernest Giralt, head of the Peptides and Proteins Lab, who has many years of experience and is a recognised expert in peptide chemistry and new systems of through which to delivery drugs to the brain, such as peptide shuttles—molecules that have the capacity to carry the drug across the barrier that surrounds and protects the brain. Since the lab started its relation with these patients’ associations in 2013*, it has been developing another two projects into Friedrich’s Ataxia.